<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this paper we address methodological aspects of aetiological importance in the link between <z:mp ids='MP_0002055'>diabetes</z:mp> and mortality in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We identified nine key points on the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> pathway at which confounding may arise-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening use, stage at diagnosis, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment selection, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment complications and failures, peri-treatment mortality, competing risks for long-term mortality, effects of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> on anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies, effects of <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering treatments on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> outcome and differences in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> biology </plain></SENT>
<SENT sid="2" pm="."><plain>Two types of mortality studies were identified: (1) inception cohort studies that evaluate the effect of baseline <z:mp ids='MP_0002055'>diabetes</z:mp> on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality in general populations, and (2) cohorts of patients with a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis and pre-existing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We demonstrate, with multiple examples from the literature, that pre-existing <z:mp ids='MP_0002055'>diabetes</z:mp> affects presentation, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment, and outcome of several common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, often to varying extents </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> is associated with increased <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients, but the evidence that it influences <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific mortality is inconsistent </plain></SENT>
<SENT sid="5" pm="."><plain>In the absence of data that address the potential biases and confounders outlined in the above framework, we caution against the reporting of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality as a main endpoint in analyses determining the impact of <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering medications on risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>